Ascentage Pharma Group International (6855) Fundamentals 2026 — Revenue Analysis | SniperIQ
Ascentage Pharma Group International (6855) is a CN-listed Healthcare company in Biotechnology with a market capitalization of HK
7.60 on the HKSE. This SniperIQ fundamentals page covers Ascentage Pharma Group International's valuation, profitability (net margin -216.7%), revenue (¥559M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Ascentage Pharma Group International's market cap?
Ascentage Pharma Group International (6855) has a market capitalization of approximately HK
7.60 on the HKSE. Market cap moves with the live share price.What is Ascentage Pharma Group International's P/E ratio?
Ascentage Pharma Group International's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 9.1x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Ascentage Pharma Group International?
Ascentage Pharma Group International runs a net profit margin of -216.7%, a gross margin of 84.1%, and an operating margin of -210.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Ascentage Pharma Group International generate?
Ascentage Pharma Group International reported revenue of ¥559M for fiscal year 2025, with net income of -¥1.2B and earnings per share (EPS) of -3.4. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Ascentage Pharma Group International pay a dividend?
Ascentage Pharma Group International does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Ascentage Pharma Group International financially healthy?
Ascentage Pharma Group International carries a debt-to-equity ratio of 1.49x and a current ratio of 1.79x, with a market beta of 0.66. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Ascentage Pharma Group International a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Ascentage Pharma Group International (6855) the key facts are: market cap HK
Track Ascentage Pharma Group International's full fundamentals live
Get Ascentage Pharma Group International's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.